Please login to the form below

Not currently logged in
Email:
Password:

Patent cliff losses set to cost pharma $65bn by 2019

Lilly, AZ and Otsuka to be hit hard, says GlobalData

Pharma spendingPharma firms should brace themselves for an estimated $65bn drop in sales by 2019 due to patent expiries on several leading drugs, according a new report.

Research and consulting company GlobalData says a significant proportion of losses will come from the central nervous system (CNS) treatment sector, with Otsuka, Eli Lilly and AstraZeneca (AZ) expected to be hit hard.

For Lilly and AZ it continues their sales declines in the area as their flagship brands continue to suffer.

GlobalData analyst Adam Dion said: “AZ, CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine), a treatment for bipolar disorder. GlobalData estimates AZ's share to have been around 9% in 2010, which has now fallen to only 3% in 2013.

“Eli Lilly's market share declines from 14.3% in 2010 to 11.2% in 2013, primarily thanks to decreasing sales of Zyprexa (olanzapine). Zyprexa sales have plummeted from over $5bn to $1,2bn over the same period as a result of the drug losing its US patent exclusivity in 2011.”

Dion added that, although Otsuka's anti-psychotic drug Abilify (aripiprazole) - co-owned with Bristol-Myers Squibb - was the sales leader in CNS, bringing in $9.5bn in 2013, the future of the drug is not so positive with its US patent expiration in 2015, leading to a potential loss of $6.2bn by 2019.

However, industry-wide the picture may be more positive. Research from IMS Health published last month predicted global medicines spending would grow by $305-335bn in the five years to the end of 2018. 

Article by
Kirstie Pickering

16th December 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics